Tarsons Products has scheduled an analyst and institutional investor meeting for June 11, 2026. The company's officials will participate in the virtual conference to discuss publicly available information, with no Unpublished Price Sensitive Information (UPSI) intended to be shared.

The meeting is being hosted by Choice Broking and is classified as a group meeting. It is scheduled to take place between 16:00 P.M. and 17:00 P.M. IST. The company noted that the schedule is subject to changes due to exigencies on the part of the host or the company.

Meeting Details

The disclosure was made pursuant to Regulation 30(6) read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Santosh Kumar Agarwal, the CFO, Company Secretary & Compliance Officer, signed the intimation on June 06, 2026.

tarsons products completed the second tranche of an equity infusion totaling EUR 552,000 in its wholly-owned subsidiary, Tarsons Life Science Pte. Ltd., on June 03, 2026. This investment is part of a total approved equity infusion of EUR 3,000,000. The funds will be utilized by the Singapore-based subsidiary for the repayment of its bank loan, payment of interest, and meeting general corporate purposes and operational requirements.

Pursuant to the investment, the company subscribed to 184 equity shares of Tarsons Life Science Pte. Ltd. at a nominal value of EUR 3,000 per share. The transaction was completed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The subsidiary, incorporated on November 10, 2023, operates as a non-operating financial holding company and special purpose vehicle.

The first tranche of this investment, amounting to EUR 300,000, was completed on April 09, 2026, with the subscription of 100 equity shares. The latest tranche maintains the status of Tarsons Life Science Pte. Ltd. as a wholly-owned subsidiary of Tarsons Products, with no change in ownership percentage. The transaction is classified as a related party transaction conducted at arm’s length.

Investment Details

The following table outlines the specifics of the equity infusion:

Subsidiary Financials

Tarsons Life Science Pte. Ltd. has reported nil turnover since its incorporation. The financial performance for the past three fiscal years is detailed below:

The board of directors initially approved the total equity infusion of EUR 3,000,000 on February 06, 2026. Tarsons Products stated it will inform the stock exchanges regarding the completion of any subsequent tranches of the approved investment as they occur.